58 studies found for:    Open Studies | "Urticaria"
Show Display Options
Rank Status Study
21 Not yet recruiting Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
Condition: Chronic Idiopathic Urticaria
Intervention: Drug: Omalizimab
22 Unknown  Efficacy Study of Canakinumab to Treat Urticaria
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Canakinumab;   Drug: Placebo
23 Not yet recruiting A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)
Condition: Chronic Idiopathic Urticaria
Intervention: Drug: Omalizumab
24 Recruiting OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
Condition: Chonic Spontaneous Urticaria
Intervention: Drug: omalizumab
25 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
26 Recruiting Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction.
Condition: Acute Urticaria
Interventions: Drug: JDP-205 Injection;   Drug: Diphenhydramine
27 Recruiting Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
28 Recruiting PF and FeNO and Clinical Characteristics in Children Being Diagnosed Due to Suspicion of Allergic Diseases
Conditions: Asthma;   Allergic Rhinitis;   Atopic Dermatitis;   Urticaria;   Healthy
Intervention: Other: No intervention
29 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
30 Unknown  Platelet Activation in Chronic Inflammatory Skin Diseases
Conditions: Urticaria;   Atopic Dermatitis
Intervention: Procedure: Blood sampling
31 Recruiting Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients
Condition: Chronic Spontaneous Uriticaria
Interventions: Biological: Omalizumab;   Other: Placebo
32 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
33 Recruiting Use of Tamoxifen in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention:
34 Unknown  Molecular Mechanisms and Diagnosis of Mastocytosis
Condition: Mastocytosis
Intervention:
35 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
36 Not yet recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
37 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
38 Recruiting Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Conditions: Aggressive Systemic Mastocytosis (ASM);   Systemic Mastocytosis With Associated Clonal Hematological Non-mast Cell Lineage Disease (SM-AHNMD);   Mast Cell Leukemia (MCL);   Smoldering Systemic Mastocytosis (SSM);   Indolent Systemic Mastocytosis (ISM) [ISM Subgroup Fully Recruited]
Intervention: Other: Interview
39 Unknown  Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Advanced Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
40 Unknown  Evaluation of Response of Dasatinib to Treat Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Dasatinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-58) Show next page of results    Last Page
Indicates status has not been verified in more than two years